Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability

Pharmaceutical Research

Volumn 32, Issue 11, 2015, Pages 3541-3571

  Singh, Satish K ^a   Luisi, Donna L ^a   Pak, Roger H ^a  

^a PFIZER INC   (United States)

Author keywords

antibody drug conjugate; formulation; linker; payload; physicochemical characteristics

Indexed keywords

ANTIBODY CONJUGATE; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; BRENTUXIMAB VEDOTIN; CALICHEAMICIN; CANTUZUMAB MERTANSINE; COLTUXIMAB RAVTANSINE; CYSTEINE; DOLASTATIN 10; DOXORUBICIN; DRUG ANTIBODY; FC RECEPTOR; GEMTUZUMAB OZOGAMICIN; GLEMBATUMUMAB VEDOTIN; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; INOTUZUMAB OZOGAMICIN; LYSINE; MACROGOL; MAYTANSINE; METHOTREXATE; MONOCLONAL ANTIBODY; NATURAL PRODUCT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRASTUZUMAB EMTANSINE; VEDOTIN; DRUG;

ANALYTIC METHOD; ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; BINDING AFFINITY; BONE MARROW TOXICITY; CANCER THERAPY; CELL INTERACTION; CONFORMATIONAL TRANSITION; DISULFIDE BOND; DRUG DESIGN; DRUG FORMULATION; GLYCOSYLATION; HUMAN; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; IMMUNOGENICITY; LIVER TOXICITY; MOLECULAR MODEL; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; STEREOSPECIFICITY; THERMOSTABILITY; ANIMAL; ANTIBODY COMBINING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG STABILITY; PROTEIN ENGINEERING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; BINDING SITES, ANTIBODY; DRUG DESIGN; DRUG STABILITY; GLYCOSYLATION; HUMANS; IMMUNOCONJUGATES; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PHYSICOCHEMICAL PHENOMENA; PROTEIN ENGINEERING;

EID: 84943582403     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1704-4     Document Type: Review

References (201)

1. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278-87.
2. Sapra P, Shor B. Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol Ther. 2013;138(3):452-69.
3. Glennie MJ, van de Winkel JG. Renaissance of cancer therapeutic antibodies. Drug Discov Today. 2003;8(11):503-10.
4. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23(9):1137-46.
5. de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, et al. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18(21):5845-9.
6. FDA approves new treatment for late-stage breast cancer. [press release]. Washington, DC USA, 2/26/2013 2013.
7. Jain N, Smith SW, Ghone S, Tomczuk B. Current ADC linker chemistry. Pharm Res. 2015. doi: 10.1007/s11095-015-1657-7.
8. McCombs JR, Owen SC. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J. 2015;17(2):339-51.
9. Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, et al. Antibody-drug conjugates: current status and future directions. Drug Discov Today. 2014;19(7):869-81.
10. Govindan SV, Goldenberg DM. Designing immunoconjugates for cancer therapy. Expert Opin Biol Ther. 2012;12(7):873-90.
11. Janthur WD, Cantoni N, Mamot C. Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. Int J Mol Sci. 2012;13(12):16020-45.
12. Yordanov G. Advanced strategies for drug delivery in nanomedicine. Progr Colloid Interf Sci. 2014;4:3-36. Colloid and Interface Chemistry for Nanotechnology.
13. Arias JL. Drug delivery strategies in targeting cancer: current concepts and future developments. Curr Drug Targets. 2011;12(8):1094-5.
14. Basile L, Pignatello R, Passirani C. Active targeting strategies for anticancer drug nanocarriers. Curr Drug Deliv. 2012;9(3):255-68.
15. Alexander-Bryant AA, Vanden Berg-Foels WS, Wen X. Bioengineering strategies for designing targeted cancer therapies. Adv Cancer Res. 2013;118:1-59.
16. Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. mAbs. 2014;6(1):34-45.
17. Sievers EL, Linenberger M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol. 2001;13(6):522-7.
18. Ravandi F. Gemtuzumab ozogamicin: one size does not fit all-the case for personalized therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(4):349-51.
19. Goldmacher VS, Kovtun YV. Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther Deliv. 2011;2(3):397-416.
20. Adair JR, Howard PW, Hartley JA, Williams DG, Chester KA. Antibody-drug conjugates - a perfect synergy. Expert Opin Biol Ther. 2012;12(9):1191-206.
21. Adcetris. Prescribing information2013 February 2014. Available from: http://www.ich.org/prodcts/guidelines/quality/article/quality-guidelines.html.
22. Kadcyla. Prescribing information2013 February 2014. Available from: http://www.gene.com/download/pdf/kadcyla-prescribing.pdf.
23. Herceptin. Prescribing information2014 May 2014. Available from: http://www.gene.com/download/pdf/herceptin-prescribing.pdf.
24. Clark M. Antibody humanization: a case of the 'Emperor's new clothes'? Immunol Today. 2000;21(8):397-402.
25. Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. mAbs. 2013;5(1):13-21.
26. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23(9):1147-57.
27. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8(10):2861-71.
28. Salfeld JG. Isotype selection in antibody engineering. Nat Biotechnol. 2007;25(12):1369-72.
29. Adcetris. Adcetris Assessment report EMA/702390/2012 Available from: www.ema.europa.eu.
30. Kadcyla. Kadcyla Assessment report EMA/749228/2013 Available from: www.emea.europa.eu.
31. McDonagh CF, Kim KM, Turcott E, Brown LL, Westendorf L, Feist T, et al. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol Cancer Ther. 2008;7(9):2913-23.
32. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys. 2012;526(2):159-66.
33. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther. 2007;7(9):1401-13.
34. Ratner M. Genentech's glyco-engineered antibody to succeed Rituxan. Nat Biotechnol. 2014;32(1):6-7.
35. Putnam WS, Prabhu S, Zheng Y, Subramanyam M, Wang YM. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol. 2010;28(10):509-16.
36. Jones AJ, Papac DI, Chin EH, Keck R, Baughman SA, Lin YS, et al. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology. 2007;17(5):529-40.
37. Alessandri L, Ouellette D, Acquah A, Rieser M, Leblond D, Saltarelli M, et al. Increased serum clearance of oligomannose species present on a human IgG1 molecule. mAbs. 2012;4(4):509-20.
38. Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology. 2011;21(7):949-59.
39. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23(9):1126-36.
40. Liu H, Chumsae C, Gaza-Bulseco G, Hurkmans K, Radziejewski CH. Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. Anal Chem. 2010;82(12):5219-26.
41. Liu H, May K. Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. mAbs. 2012;4(1):17-23.
42. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(20):7063-70.
43. Beckley NS, Lazzareschi KP, Chih HW, Sharma VK, Flores HL. Investigation into temperature-induced aggregation of an antibody drug conjugate. Bioconjug Chem. 2013;24(10):1674-83.
44. Guo J, Kumar S, Prashad A, Starkey J, Singh SK. Assessment of physical stability of an antibody drug conjugate by higher order structure analysis: impact of thiol- maleimide chemistry. Pharm Res. 2014;31(7):1710-23.
45. Sun MM, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, Torgov MY, et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem. 2005;16(5):1282-90.
46. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;30(7):631-7.
47. Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16(19):4769-78.
48. Wakankar AA, Feeney MB, Rivera J, Chen Y, Kim M, Sharma VK, et al. Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes. Bioconjug Chem. 2010;21(9):1588-95.
49. Wang L, Amphlett G, Blattler WA, Lambert JM, Zhang W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Prot Sci Publ Prot Soc. 2005;14(9):2436-46.
50. Bender B, Leipold DD, Xu K, Shen BQ, Tibbitts J, Friberg LE. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an Antibody-Drug Conjugate (ADC) for treatment of metastatic breast cancer. AAPS J. 2014;16(5):994-1008.
51. Mylotarg. Prescribing information 2010 [cited 2014 March]. Available from: http://www.drugs.com/pro/mylotarg.html.
52. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103(5):1807-14.
53. McDonagh CF, Turcott E, Westendorf L, Webster JB, Alley SC, Kim K, et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Prot Eng Des Sel PEDS. 2006;19(7):299-307.
54. Klinguer-Hamour C, Strop P, Shah DK, Ducry L, Xu A, Beck A. World antibody-drug conjugate summit, October 15-16, 2013, San Francisco, CA. mAbs. 2014;6(1):18-29.
55. Miao D, editor Panel screenings, powerful modular ADC technology platforms from target to IND. IBC Bioconjugates; 2013 June 26-28; Coronado, CA.
56. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26(8):925-32.
57. Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem. 2011;22(10):1994-2004.
58. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30(2):184-9.
59. Damle NK. Antibody-drug conjugates ace the tolerability test. Nat Biotechnol. 2008;26(8):884-5.
60. Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008;19(3):759-65.
61. Voynov V, Chennamsetty N, Kayser V, Wallny HJ, Helk B, Trout BL. Design and application of antibody cysteine variants. Bioconjug Chem. 2010;21(2):385-92.
62. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Prediction of aggregation prone regions of therapeutic proteins. J Phys Chem B. 2010;114(19):6614-24.
63. Gomez N, Ouyang J, Nguyen MD, Vinson AR, Lin AA, Yuk IH. Effect of temperature, pH, dissolved oxygen, and hydrolysate on the formation of triple light chain antibodies in cell culture. Biotechnol Prog. 2010;26(5):1438-45.
64. Gomez N, Vinson AR, Ouyang J, Nguyen MD, Chen XN, Sharma VK, et al. Triple light chain antibodies: factors that influence its formation in cell culture. Biotechnol Bioeng. 2010;105(4):748-60.
65. Strop P, Liu SH, Dorywalska M, Delaria K, Dushin RG, Tran TT, et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 2013;20(2):161-7.
66. Jeger S, Zimmermann K, Blanc A, Grunberg J, Honer M, Hunziker P, et al. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew Chem. 2010;49(51):9995-7.
67. Ohtsuka T, Sawa A, Kawabata R, Nio N, Motoki M. Substrate specificities of microbial transglutaminase for primary amines. J Agric Food Chem. 2000;48(12):6230-3.
68. Farias SE, Strop P, Delaria K, Galindo Casas M, Dorywalska M, Shelton DL, et al. Mass spectrometric characterization of transglutaminase based site-specific antibody-drug conjugates. Bioconjug Chem. 2014;25(2):240-50.
69. Behrens CR, Liu B. Methods for site-specific drug conjugation to antibodies. mAbs. 2014;6(1):46-53.
70. Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A. 2012;109(40):16101-6.
71. Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, et al. A general approach to site-specific antibody drug conjugates. Proc Natl Acad Sci U S A. 2014;111(5):1766-71.
72. Sutro. Sutro Biopharma Technology 2013 [cited 2014 08Feb]. Available from: http://www.sutrobio.com/tech/index.html.
73. Synaffix connecting molecules 2014 [cited 2014 07Feb]. Available from: www.synaffix.com.
74. van Hest JC, van Delft FL. Protein modification by strain-promoted alkyne-azide cycloaddition. Chembiochem Eur J Chem Biol. 2011;12(9):1309-12.
75. Boeggeman E, Ramakrishnan B, Pasek M, Manzoni M, Puri A, Loomis KH, et al. Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection. Bioconjug Chem. 2009;20(6):1228-36.
76. Starling JJ, Maciak RS, Hinson NA, Nichols CL, Briggs SL, Laguzza BC, et al. In vivo antitumor activity of a panel of four monoclonal antibody-vinca alkaloid immunoconjugates which bind to three distinct epitopes of carcinoembryonic antigen. Bioconjug Chem. 1992;3(4):315-22.
77. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science. 1993;261(5118):212-5.
78. Safavy A, Georg GI, Vander Velde D, Raisch KP, Safavy K, Carpenter M, et al. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure. Bioconjug Chem. 2004;15(6):1264-74.
79. Flygare JA, Pillow TH, Aristoff P. Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des. 2013;81(1):113-21.
80. Gerber HP, Koehn FE, Abraham RT. The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat Prod Rep. 2013;30(5):625-39.
81. Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 1993;53(14):3336-42.
82. Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins. 2011;3(7):848-83.
83. Smith AL, Nicolaou KC. The enediyne antibiotics. J Med Chem. 1996;39(11):2103-17.
84. Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Flowers DA, et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem. 2002;13(1):40-6.
85. Bai RL, Pettit GR, Hamel E. Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10. Biochem Pharmacol. 1990;40(8):1859-64.
86. Pettit GR. The dolastatins. Progress in the chemistry of organic natural products. Prog Chem Org Nat Prod. 1997;70:1-19.
87. Fennell BJ, Carolan S, Pettit GR, Bell A. Effects of the antimitotic natural product dolastatin 10, and related peptides, on the human malarial parasite Plasmodium falciparum. J Antimicrob Chemother. 2003;51(4):833-41.
88. Pettit RK, Pettit GR, Hazen KC. Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformans. Antimicrob Agents Chemother. 1998;42(11):2961-5.
89. Bai R, Roach MC, Jayaram SK, Barkoczy J, Pettit GR, Luduena RF, et al. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity. Biochem Pharmacol. 1993;45(7):1503-15.
90. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778-84.
91. Seattle-Genetics. 2014.
92. Kupchan SM, Komoda Y, Court WA, Thomas GJ, Smith RM, Karim A, et al. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc. 1972;94(4):1354-6.
93. Higashide E, Asai M, Ootsu K, Tanida S, Kozai Y, Hasegawa T, et al. Ansamitocin, a group of novel maytansinoid antibiotics with antitumour properties from Nocardia. Nature. 1977;270(5639):721-2.
94. Remillard S, Rebhun LI, Howie GA, Kupchan SM. Antimitotic activity of the potent tumor inhibitor maytansine. Science. 1975;189(4207):1002-5.
95. Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem. 2006;49(14):4392-408.
96. Kupchan SM, Sneden AT, Branfman AR, Howie GA, Rebhun LI, McIvor WE, et al. Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids. J Med Chem. 1978;21(1):31-7.
97. Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blattler WA, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res. 1992;52(1):127-31.
98. ImmunoGen, Inc. Announces activity reported with SAR3419 plus rituxan in difficult-to-treat patient population [press release]. December 9, 2013 2013.
99. Takahashi I, Takahashi K, Ichimura M, Morimoto M, Asano K, Kawamoto I, et al. Duocarmycin A, a new antitumor antibiotic from Streptomyces. J Antibiot. 1988;41(12):1915-7.
100. Boger DL. The duocarmycins: synthetic and mechanistic studies. Acc Chem Res. 1995;28(1):20-9.
101. Wolfe AL, Duncan KK, Lajiness JP, Zhu K, Duerfeldt AS, Boger DL. A fundamental relationship between hydrophobic properties and biological activity for the duocarmycin class of DNA-alkylating antitumor drugs: hydrophobic-binding-driven bonding. J Med Chem. 2013;56(17):6845-57.
102. Thevanayagam L, Bell A, Chakraborty I, Sufi B, Gangwar S, Zang A, et al. Novel detection of DNA-alkylated adducts of antibody-drug conjugates with potentially unique preclinical and biomarker applications. Bioanalysis. 2013;5(9):1073-81.
103. Clinicaltrials.gov. Study of MDX-1203 in subjects with advanced/recurrent clear cell renal Cell Carcinoma (ccRCC) or relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL) 2014 [March 26, 2014]. Clinical trials database]. Available from: http://clinicaltrials.gov/ct2/show/NCT00944905?term=mdx-1203&rank=1.
104. Sutherland MSK, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122(8):1455-63.
105. Moldenhauer G, Salnikov AV, Luttgau S, Herr I, Anderl J, Faulstich H. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst. 2012;104(8):622-34.
106. Nolting B. Linker technologies for antibody-drug conjugates. Meth Mol Biol (Clifton, NJ). 2013;1045:71-100.
107. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2010;21(1):5-13.
108. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13(1):47-58.
109. Ambrx. 2014 [February 28, 2014]. Ambrx company website]. Available from: www.ambrx.com.
110. DiJoseph JF, Popplewell A, Tickle S, Ladyman H, Lawson A, Kunz A, et al. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol Immunother CII. 2005;54(1):11-24.
111. Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M, et al. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem. 2011;22(4):717-27.
112. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280-90.
113. Shen BQ, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, et al. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab. 2012;13(7):901-10.
114. Allozyne. 2014 [February 28, 2014]. Allozyne company website]. Available from: www.allozyne.com.
115. Nairn NW, Shanebeck KD, Wang A, Graddis TJ, VanBrunt MP, Thornton KC, et al. Development of copper-catalyzed azide-alkyne cycloaddition for increased in vivo efficacy of interferon beta-1b by site-specific PEGylation. Bioconjug Chem. 2012;23(10):2087-97.
116. Aijun Wang NWN, Marelli M, Grabstein K. Protein engineering with non-natural amino Acids. In: Kaumaya PP, editor. Protein Engineering: InTech; 2012.
117. Redwood. Redwood Bioscience; 2014 [February 25, 2014]. Redwood Bioscience company website]. Available from: www.redwoodbioscience.com.
118. Carrico IS, Carlson BL, Bertozzi CR. Introducing genetically encoded aldehydes into proteins. Nat Chem Biol. 2007;3(6):321-2.
119. Rabuka D, Rush JS, deHart GW, Wu P, Bertozzi CR. Site-specific chemical protein conjugation using genetically encoded aldehyde tags. Nat Protoc. 2012;7(6):1052-67.
120. Agarwal P, Kudirka R, Albers AE, Barfield RM, de Hart GW, Drake PM, et al. Hydrazino-Pictet-Spengler ligation as a biocompatible method for the generation of stable protein conjugates. Bioconjug Chem. 2013;24(6):846-51.
121. Drake PM, Albers AE, Baker J, Banas S, Barfield RM, Bhat AS, et al. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjug Chem. 2014;25(7):1331-41.
122. Balan S, Choi JW, Godwin A, Teo I, Laborde CM, Heidelberger S, et al. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. Bioconjug Chem. 2007;18(1):61-76.
123. Thayer AM. Building antibody-drug conjugates. Chem Eng News. 2014;13-20.
124. Castaneda L, Maruani A, Schumacher FF, Miranda E, Chudasama V, Chester KA, et al. Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation. Chem Commun. 2013;49(74):8187-9.
125. Schumacher FF, Nobles M, Ryan CP, Smith ME, Tinker A, Caddick S, et al. In situ maleimide bridging of disulfides and a new approach to protein PEGylation. Bioconjug Chem. 2011;22(2):132-6.
126. Schumacher FF, Sanchania VA, Tolner B, Wright ZV, Ryan CP, Smith ME, et al. Homogeneous antibody fragment conjugation by disulfide bridging introduces 'spinostics'. Sci Rep. 2013;3:1525.
127. Igenica. 2014 [March 9, 2014]. Igenica Company Website]. Available from: www.igenica.com.
128. Cukier-Meisner E. Appreciating in private. BioCentury. 2014.
129. Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical characterization of antibody drug conjugates. mAbs. 2011;3(2):161-72.
130. Willner D, Trail PA, Hofstead SJ, King HD, Lasch SJ, Braslawsky GR, et al. (6-Maleimidocaproyl)hydrazone of doxorubicin - a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug Chem. 1993;4(6):521-7.
131. Stephan JP, Kozak KR, Wong WL. Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates. Bioanalysis. 2011;3(6):677-700.
132. Adem YT, Schwarz KA, Duenas E, Patapoff TW, Galush WJ, Esue O. Auristatin antibody drug conjugate physical instability and the role of drug payload. Bioconjug Chem. 2014;25(4):656-64.
133. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458-65.
134. Zolls S, Tantipolphan R, Wiggenhorn M, Winter G, Jiskoot W, Friess W, et al. Particles in therapeutic protein formulations, Part 1: overview of analytical methods. J Pharm Sci. 2012;101(3):914-35.
135. Singh SK, Afonina N, Awwad M, Bechtold-Peters K, Blue JT, Chou D, et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci. 2010;99(8):3302-21.
136. Singh SK, Toler MR. Monitoring of subvisible particles in therapeutic proteins. Meth Mol Biol (Clifton, NJ). 2012;899:379-401.
137. USP<1787>. Measurement of subvisible particulate matter in therapeutic protein injections. In: USP, editor. Washington, DC, USA 2014.
138. Hudecz F, Garnett MC, Khan T, Baldwin RW. The influence of synthetic conditions on the stability of methotrexate-monoclonal antibody conjugates determined by reversed phase high performance liquid chromatography. Biomed Chromatogr BMC. 1992;6(3):128-32.
139. Greenfield RS, Kaneko T, Daues A, Edson MA, Fitzgerald KA, Olech LJ, et al. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. Cancer Res. 1990;50(20):6600-7.
140. Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(2):211-22.
141. Buckwalter M, Dowell JA, Korth-Bradley J, Gorovits B, Mayer PR. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacol. 2004;44(8):873-80.
142. Ingle GS, Chan P, Elliott JM, Chang WS, Koeppen H, Stephan JP, et al. High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br J Haematol. 2008;140(1):46-58.
143. Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006;281(15):10540-7.
144. Law CL, Cerveny CG, Gordon KA, Klussman K, Mixan BJ, Chace DF, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(23):7842-51.
145. Pan LY, Salas-Solano O, Valliere-Douglass JF. Conformation and dynamics of interchain cysteine-linked antibody-drug conjugates as revealed by hydrogen/deuterium exchange mass spectrometry. Anal Chem. 2014;86(5):2657-64.
146. Acchione M, Kwon H, Jochheim CM, Atkins WM. Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates. mAbs. 2012;4(3):362-72.
147. Boylan NJ, Zhou W, Proos RJ, Tolbert TJ, Wolfe JL, Laurence JS. Conjugation site heterogeneity causes variable electrostatic properties in Fc conjugates. Bioconjug Chem. 2013;24(6):1008-16.
148. Maeda E, Urakami K, Shimura K, Kinoshita M, Kakehi K. Charge heterogeneity of a therapeutic monoclonal antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin. J Chromatogr A. 2010;1217(45):7164-71.
149. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-75.
150. Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm Res. 1989;6(11):903-18.
151. Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst. 1993;10(4):307-77.
152. Siegel MM, Tabei K, Kunz A, Hollander IJ, Hamann RR, Bell DH, et al. Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry. Anal Chem. 1997;69(14):2716-26.
153. Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11(2 Pt 1):843-52.
154. Carl PL, Chakravarty PK, Katzenellenbogen JA. A novel connector linkage applicable in prodrug design. J Med Chem. 1981;24(5):479-80.
155. Dubowchik GM, Firestone RA. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg Med Chem Lett. 1998;8(23):3341-6.
156. Dubowchik GM, Mosure K, Knipe JO, Firestone RA. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett. 1998;8(23):3347-52.
157. Lewis MR, Shively JE. Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions. Bioconjug Chem. 1998;9(1):72-86.
158. Lin D, Saleh S, Liebler DC. Reversibility of covalent electrophile-protein adducts and chemical toxicity. Chem Res Toxicol. 2008;21(12):2361-9.
159. Baldwin AD, Kiick KL. Tunable degradation of maleimide-thiol adducts in reducing environments. Bioconjug Chem. 2011;22(10):1946-53.
160. Fishkin N, Maloney EK, Chari RV, Singh R. A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions. Chem Commun. 2011;47(38):10752-4.
161. Dere R, Yi JH, Lei C, Saad OM, Huang C, Li Y, et al. PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. Bioanalysis. 2013;5(9):1025-40.
162. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185(2):129-88.
163. Myers AG, Cohen SB, Kwon BM. A study of the reaction of calicheamicin.Gamma.1 with glutathione in the presence of double-stranded DNA. J Am Chem Soc. 1994;116(4):1255-71.
164. Hollander I, Kunz A, Hamann PR. Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. Bioconjug Chem. 2008;19(1):358-61.
165. Safavy A, Bonner JA, Waksal HW, Buchsbaum DJ, Gillespie GY, Khazaeli MB, et al. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug Chem. 2003;14(2):302-10.
166. Zhao RY, Wilhelm SD, Audette C, Jones G, Leece BA, Lazar AC, et al. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem. 2011;54(10):3606-23.
167. Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010;70(6):2528-37.
168. King HD, Dubowchik GM, Mastalerz H, Willner D, Hofstead SJ, Firestone RA, et al. Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. J Med Chem. 2002;45(19):4336-43.
169. Chari R, Jerath K, Badkar AV, Kalonia DS. Long- and short-range electrostatic interactions affect the rheology of highly concentrated antibody solutions. Pharm Res. 2009;26(12):2607-18.
170. Yadav S, Laue TM, Kalonia DS, Singh SN, Shire SJ. The influence of charge distribution on self-association and viscosity behavior of monoclonal antibody solutions. Mol Pharm. 2012;9(4):791-802.
171. Dominy BN, Minoux H, Brooks 3rd CL. An electrostatic basis for the stability of thermophilic proteins. Proteins. 2004;57(1):128-41.
172. Wang J, Dang V, Zhao W, Lu D, Rivera BK, Villamena FA, et al. Perchlorotrityl radical-fluorophore conjugates as dual fluorescence and EPR probes for superoxide radical anion. Bioorg Med Chem. 2010;18(2):922-9.
173. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm. 2005;289(1-2):1-30.
174. Philo J. A critical review of methods for size characterization of non-particulate protein aggregates. Curr Pharm Biotechnol. 2009;10:359-72.
175. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res. 1997;14(8):969-75.
176. Ducry L. Challenges in the development and manufacturing of antibody-drug conjugates. Meth Mol Biol (Clifton, NJ). 2012;899:489-97.
177. Wang W, Cui TY, Wang YJ, Martin-Moe S. Oxidation of protein by vaporized sanitizing agents. PDA J Pharm Sci Technol / PDA. 2004;58(3):121-9.
178. Singh SK, Kolhe P, Wang W, Nema S. Large-scale freezing of biologics. A practioner's review Part One: Fundamental aspects. BioProcess Int. 2009;7(9):32-44.
179. Singh SK, Kolhe P, Wang W, Nema S. Large-scale freezing of biologics. A practioner's reveiw. Part 2: practical advice. BioProcess Int. 2009;7(10):34-42.
180. Singh SK, Kolhe P, Mehta AP, Chico SC, Lary AL, Huang M. Frozen state storage instability of a monoclonal antibody: aggregation as a consequence of trehalose crystallization and protein unfolding. Pharm Res. 2011;28(4):873-85.
181. Zhou R, Schlam RF, Yin S, Gandhi RB, Adams ML. Scale considerations for selection of saccharide excipients for liquid formulations. J Pharm Sci. 2011;100(4):1605-6.
182. Kolhe P, Mehta AP, Lary AL, Chico SC, Singh SK. Large-scale freezing of biologics (Part III). Understanding frozen-state protein and solute concentration changes in Celsius bags. BioPharm Int. 2012;25(10):40-8.
183. Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol. 2007;12(5):505-23.
184. Kolhe P, Amend E, Singh SK. Impact of freezing on pH of buffered solutions and consequences for monoclonal antibody aggregation. Biotechnol Prog. 2010;26(3):727-33.
185. Metcalfe JW. Microbiological quality of drug products after penetration of the container system for dose preparation prior to patient administration. Am Pharm Rev. 2009;12(1):84-9.
186. FDA U. Guidance for Industry. Dosage and administration section of labeling for human prescriptiopn drug and biological products - content and format. 2010.
187. Demeule B, Palais C, Machaidze G, Gurny R, Arvinte T. New methods allowing the detection of protein aggregates: a case study on trastuzumab. mAbs. 2009;1(2):142-50.
188. Sreedhara A, Glover ZK, Piros N, Xiao N, Patel A, Kabakoff B. Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions. J Pharm Sci. 2012;101(1):21-30.
189. Baertschi SW, Clapham D, Foti C, Jansen PJ, Kristensen S, Reed RA, et al. Implications of in-use photostability: proposed guidance for photostability testing and labeling to support the administration of photosensitive pharmaceutical products, part 1: drug products administered by injection. J Pharm Sci. 2013;102(11):3888-99.
190. Kumru OS, Liu J, Ji JA, Cheng W, Wang YJ, Wang T, et al. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags. J Pharm Sci. 2012;101(10):3636-50.
191. Mikisinski SP, Shapiro M. Regulatory considerations for antibody-drug conjugates2012 February 2014. Available from: http://www.fda.gov/downloads/AboutFDA/CentersOffices/ OfficeofMedicalProductsandTobacco/CDER/UCM341177.pdf.
192. Impurities in new drug substances. 2006.
193. Q3B(R2) I. Impurities in new drug products. 2006.
194. Nonclinical evaluation for anticancer pharmaceuticals. 2009.
195. EMEA. Guideline on the limits of genotoxic impurities. EMEA/CHMP/QWP/251344/2006. 2006.
196. Jones MT, Gong HH, Lee DH, Zheng J, Kott L, Miller S, et al. Risk assesment for small molceule impurities in Antibody Drug Conjugaes (ADC). BioPharm Int. 2014;27(tbd):tbd.
197. Harris J, Jacobson FS, Jochheim CM, Amphlett G, Francissen K, McLeod L. Uniting small molecule and biologic drug perspectives. Analytical characterization and regulatory considerations for antibody-drug conjugates. BioProcess Int. 2011;9(8):12-22.
198. Xiao YQ, Halford A, Hayes RN. Meeting challenges for analysis of antibody-drug conjugates. BioProcess Int. 2012;25(10):60-3.
199. Good manufacturing practice guide for active pharmaceutical ingredients. 2000.
200. Development and manufacture of drug substances (chemical entities and biotechnological/biologic entities). 2012.
201. Shapiro MA, Chen X-H. Regulatory considerations when developing assays for the characterization and quality control of antibody-drug conjugates. Am Lab. 2012;44(8):1-7.